25 related articles for article (PubMed ID: 6539116)
1. Sulindac and sulindac metabolites in nipple aspirate fluid and effect on drug targets in a phase I trial.
Thompson PA; Hsu CH; Green S; Stopeck AT; Johnson K; Alberts DS; Chow HH
Cancer Prev Res (Phila); 2010 Jan; 3(1):101-7. PubMed ID: 20051377
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic model for cancer chemoprevention with sulindac in healthy subjects.
Berg AK; Mandrekar SJ; Ziegler KL; Carlson EC; Szabo E; Ames MM; Boring D; Limburg PJ; Reid JM;
J Clin Pharmacol; 2013 Apr; 53(4):403-12. PubMed ID: 23436338
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacokinetics of sulindac. A dynamic old drug.
Davies NM; Watson MS
Clin Pharmacokinet; 1997 Jun; 32(6):437-59. PubMed ID: 9195115
[TBL] [Abstract][Full Text] [Related]
4. Hepatic drug metabolism and aging.
Durnas C; Loi CM; Cusack BJ
Clin Pharmacokinet; 1990 Nov; 19(5):359-89. PubMed ID: 2268986
[TBL] [Abstract][Full Text] [Related]
5. Chemopreventive Efficacy of Sulindac Sulfone as a Selective Apoptotic Antineoplastic Drug in Human Head and Neck Squamous Cell Carcinoma Cell Lines: A Systematic Review.
Karuppiah N; B S; Chockalingam RM; Bhupathy PK; Kalaimani G; Ramamurthi R
Cureus; 2024 Jan; 16(1):e51692. PubMed ID: 38313951
[TBL] [Abstract][Full Text] [Related]
6. Dimethyl sulfoxide inhibits bioactivation of sulindac.
Swanson BN; Boppana VK; Vlasses PH; Rotmensch HH; Ferguson RK
J Lab Clin Med; 1983 Jul; 102(1):95-101. PubMed ID: 6854139
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacokinetics of sulindac in aged patients presenting with inflammatory joint disease].
Mignot A; Lefebvre MA; Couet W; Dourthe C; Marechaud R; Fourtillan JB
Therapie; 1989; 44(4):253-6. PubMed ID: 2595642
[TBL] [Abstract][Full Text] [Related]
8. Influence of cholestyramine resin administration on single dose sulindac pharmacokinetics.
Malloy MJ; Ravis WR; Pennell AT; Hagan DR; Betagari S; Doshi DH
Int J Clin Pharmacol Ther; 1994 Jun; 32(6):286-9. PubMed ID: 7921528
[TBL] [Abstract][Full Text] [Related]
9. Sulindac disposition when given once and twice daily.
Swanson BN; Boppana VK; Vlasses PH; Holmes GI; Monsell K; Ferguson RK
Clin Pharmacol Ther; 1982 Sep; 32(3):397-403. PubMed ID: 7049504
[TBL] [Abstract][Full Text] [Related]
10. Biotransformation of sulindac in end-stage renal disease.
Gibson TP; Dobrinska MR; Lin JH; Entwistle LA; Davies RO
Clin Pharmacol Ther; 1987 Jul; 42(1):82-8. PubMed ID: 3595070
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of graded oral doses of sulindac in man.
Mattila J; Mäntylä R; Vuorela A; Lamminsivu U; Männistö P
Arzneimittelforschung; 1984; 34(2):226-9. PubMed ID: 6539116
[TBL] [Abstract][Full Text] [Related]
12. Sulindac: therapeutic implications of the prodrug/pharmacophore equilibrium.
Duggan DE
Drug Metab Rev; 1981; 12(2):325-37. PubMed ID: 7040018
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
